Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study
- Landewé, Robert
- Sieper, Joachim
- Mease, Philip
- Inman, Robert D.
- Lambert, Robert G.
- Deodhar, Atul
- Marzo-Ortega, Helena
- Magrey, Marina
- Kiltz, Uta
- Wang, Xin
- Li, Mei
- Zhong, Sheng
- Mostafa, Nael M.
- Lertratanakul, Apinya
- Pangan, Aileen L.
- Anderson, Jaclyn K.
DOIAbstract
BACKGROUND: Success of treatment withdrawal in patients with non-radiographic axial spondyloarthritis who are in remission remains unknown. The ABILITY-3 study explored the ability to withdraw adalimumab treatment in patients with non-radiographic axial spondyloarthritis who achieved sustained clinical remission after open-label treatment with adalimumab
Add to ORKG